Hydroxychloroquine failed to provide efficacy against COVID-19 infection
As published in the Cochrane Review, a team of researchers determined that hydroxychloroquine or chloroquine provided no efficacy against COVID-19.
The new research involved an analysis of a dozen previously published studies involving the use of chloroquine or hydroxychloroquine among more than 8,500 patients with COVID-19.
The studies included were based in numerous nations in the Western and Eastern world, such as the United States, China, Spain, Brazil, and Iran.
As reiterated by the research team, no efficacy for treating or preventing COVID-19 infection was established.
The findings showed that the antimalarial drug hydroxychloroquine or chloroquine should no longer be used for future research concerning COVID-19.
“This review certainly should put a line under using this drug to treat COVID-19, but some countries and health providers are still caught up in the earlier hype and prescribing the drug. We hope this review will help these practices end soon,” said Tom Fletcher, the study’s senior author, in a news release.
In 2020, one congressional and governoral figure from Montana, Greg Gianforte, reportedly engaged in securities fraud with the use of the antimalarial drug during the early phases of the COVID-19 pandemic.